Champions Oncology PE ratio CSBR

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 34.5×; Mar 2026
5-year median: 246×
5-year range: 13.1× to 448×
Peer median: 12.8×

Champions Oncology has no meaningful PE ratio today: it lost $0.08 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Mar 2026, at 34.5×.

On the days it had one over the last 5 years, its median was 246×, from 13.1× in May 2025 to 448× in Sep 2022.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	34.5×	34.2×	43.0×
2025	41.1×	13.1×	42.5×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	326×	227×	448×
2021	279×	268×	365×

Against its peers

Companies in Healthcare nearest Champions Oncology's size, closest first, today.

Company	PE ratio
CSBRChampions Oncology	n/m
SPROSpero Therapeutics	10.1×
LFVNLifevantage	14.7×
APTAlpha Pro Tech	13.6×
ATNMActinium Pharmaceuticals	4.2×
ICCCImmucell	128×
KEQUKewaunee Scientific	11.9×
NEPHNephros	22.1×
PDEXPro DEX	15.1×
PLXProtalix BioTherapeutics	11.1×
NATRNatures Sunshine Products	12.0×
Peer median	12.8×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Champions Oncology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.